HROW

SEC source: 0001493152-17-001109 · form4.xml · derivative · entry 1

SAHAREK JOHN P. · CIK 0001632091 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2027-02-01

F1 · derivative.exercise_date: Represents stock options granted under the Issuer's 2007 Stock Incentive and Awards Plan. The stock options vest in equal quarterly installments over a three year period.

SEC source: 0001493152-16-016104 · form4.xml · derivative · entry 2

LINDSTROM RICHARD L MD · CIK 0001242177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2019-12-23

F1 · kind: On December 19, 2016 Dr. Lindstrom entered into a definitive agreement to acquire 100,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.

F2 · price: The value of the Purchase Warrant included in each Unit is $0.125.

SEC source: 0001493152-16-016104 · form4.xml · nonDerivative · entry 1

LINDSTROM RICHARD L MD · CIK 0001242177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

F1 · kind: On December 19, 2016 Dr. Lindstrom entered into a definitive agreement to acquire 100,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.

SEC source: 0001493152-16-016102 · form4.xml · derivative · entry 5

BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes.

F2 · derivative.exercise_date: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes.

F2 · derivative.expiration_date: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes.

SEC source: 0001493152-16-016102 · form4.xml · derivative · entry 4

BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,000

Underlying: Common Stock · 156,000 shares

Expires 2019-12-23

F1 · kind: On December 19, 2016, the Beadore Trust dated March 20, 2015, through which Mr. Baum has voting and investment control over the securities, entered into a definitive agreement to acquire 156,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.

F3 · price: The value of the Purchase Warrant included in each Unit is $0.125.

SEC source: 0001493152-16-016102 · form4.xml · nonDerivative · entry 3

BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 442,126

F2 · security: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes.

SEC source: 0001493152-16-016102 · form4.xml · nonDerivative · entry 2

BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 525,835

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes.

SEC source: 0001493152-16-016102 · form4.xml · nonDerivative · entry 1

BAUM MARK L · CIK 0001274282 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,835

F1 · kind: On December 19, 2016, the Beadore Trust dated March 20, 2015, through which Mr. Baum has voting and investment control over the securities, entered into a definitive agreement to acquire 156,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.

SEC source: 0001493152-16-016103 · form4.xml · derivative · entry 2

BOLL ANDREW R. · CIK 0001542150 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Common Stock · 39,000 shares

Expires 2019-12-23

F1 · kind: On December 19, 2016, Mr. Boll entered into a definitive agreement to acquire 39,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.

F2 · price: The value of the Purchase Warrant included in each Unit is $0.125.

SEC source: 0001493152-16-016103 · form4.xml · nonDerivative · entry 1

BOLL ANDREW R. · CIK 0001542150 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,000

F1 · kind: On December 19, 2016, Mr. Boll entered into a definitive agreement to acquire 39,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.

SEC source: 0001493152-16-014460 · form4.xml · nonDerivative · entry 1

Kammer Robert J · CIK 0001542484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,089,827

F1 · security: Dr. Kammer, as plaintiff, entered into a settlement agreement with a third party related to a lawsuit. As settlement consideration the third party paid Dr. Kammer 95,000 shares of the Company's common stock.

SEC source: 0001641172-25-020751 · ownership.xml · derivative · entry 3

BAUM MARK L · CIK 0001274282 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 600,000 shares

Expires 2025-07-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Represents stock options granted to Mr. Baum on July 31, 2015, and amended on June 4, 2020, under the Issuer's 2007 Stock Incentive and Awards Plan, as amended. The stock option vested upon achievement and maintenance of certain Harrow common stock-price-based performance targets. The Company withheld a total of 313,338 shares from issuance to Mr. Baum for: (i) 127,346 shares withheld as consideration for the cashless exercise of the option; and (ii) an additional 185,992 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes.

F1 · derivative.exercise_date: Represents stock options granted to Mr. Baum on July 31, 2015, and amended on June 4, 2020, under the Issuer's 2007 Stock Incentive and Awards Plan, as amended. The stock option vested upon achievement and maintenance of certain Harrow common stock-price-based performance targets. The Company withheld a total of 313,338 shares from issuance to Mr. Baum for: (i) 127,346 shares withheld as consideration for the cashless exercise of the option; and (ii) an additional 185,992 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes.